pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
552
stories
8d
6 immunology targets to sustain a mammoth I&I market
biospace
8d
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
11d
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
11d
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
12d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
12d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
12d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
12d
China’s Henlius carves out $440M T-cell engager deal with Amberstone
fiercebiotech
12d
Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution
stat
13d
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
13d
Roivant reports Phase 2b lupus failure for an FcRn drug
endpoints
13d
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
fiercebiotech
13d
Immunovant ends cutaneous lupus program after phase 2 flop
fiercebiotech
14d
Compass vows to press on with FDA application despite new trial request
biospace
14d
2026 IPO blitz continues with 4 new biotech filings
biospace
14d
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
14d
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
biospace
14d
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
fiercebiotech
14d
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
15d
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
biospace
15d
Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
biospace
15d
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
15d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
15d
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
biospace
18d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
18d
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
18d
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
biopharma dive
18d
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
18d
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
biospace
18d
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
fiercebiotech
← prev
page 3 of 19
next →
